20/20 BioLabs Inc (AIDX)

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase...

Form PRE 14A - Other preliminary proxy statements

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to...

Form 8-K - Current report

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed ...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2...

Sidoti Events, LLC's May Micro-Cap Virtual Conference

NEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation...

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB